In short
Cenerimod is an investigational drug being studied as a potential treatment for systemic lupus erythematosus (SLE), a chronic autoimmune disease. This article summarizes key information from clinical trials evaluating the safety, efficacy, and pharmacological properties of cenerimod in patients with SLE and healthy volunteers. The trials aim to determine optimal dosing, assess the drug's ability to reduce SLE symptoms and disease activity, and evaluate its long-term safety profile.
At a glance
- Drug Name
- Cenerimod (also known as ACT-334441)
- Condition Studied
- Systemic Lupus Erythematosus (SLE)
- Administration
- Oral, once daily
- Dosages Studied
- 0.5 mg, 1 mg, 2 mg, 4 mg
- Primary Outcome Measures
- Change in total lymphocyte count, SLE Responder Index 4 (SRI-4) response
- Secondary Outcome Measures
- BILAG response, changes in specific SLE symptoms, safety assessments
- Trial Durations
- Range from 12 weeks to 3 years
- Safety Monitoring
- Adverse events, heart rate/rhythm, blood pressure, liver function, infections, malignancies
- Special Populations Studied
- Patients with renal or hepatic impairment, Japanese and Caucasian subjects
What is Cenerimod?
Cenerimod, also known as ACT-334441, is a new oral medication being developed to treat systemic lupus erythematosus (SLE), a chronic autoimmune disease. It is currently undergoing clinical trials to evaluate its effectiveness and safety in patients with moderate to severe SLE.
How Cenerimod Works
Cenerimod works by reducing the number of lymphocytes (a type of white blood cell) circulating in the bloodstream. In SLE, the immune system becomes overactive, and lymphocytes play a role in attacking the body's own tissues. By decreasing the number of these cells, Cenerimod aims to reduce the severity of SLE symptoms and slow down disease progression.
Conditions Treated by Cenerimod
The primary condition being targeted by Cenerimod is systemic lupus erythematosus (SLE). SLE is a complex autoimmune disease that can affect various parts of the body, including the skin, joints, kidneys, brain, and other organs. Symptoms can vary widely but often include fatigue, joint pain, skin rashes, and fever.
Clinical Trials and Research
Several clinical trials are currently underway to evaluate the efficacy and safety of Cenerimod:
- A Phase 3 study is investigating the long-term safety and tolerability of Cenerimod in adults with moderate to severe SLE. This study will last for up to 3 years and involve approximately 680 participants.
- Another Phase 3 study is evaluating the efficacy, safety, and tolerability of Cenerimod in adults with moderate to severe SLE. This study will compare Cenerimod to a placebo over a 12-month period.
- A Phase 2b study has been completed, which assessed different doses of Cenerimod (0.5 mg, 1 mg, 2 mg, and 4 mg) compared to placebo in patients with SLE.
Dosage and Administration
In the ongoing clinical trials, Cenerimod is being tested at various doses, ranging from 0.5 mg to 4 mg. It is administered as a once-daily oral tablet. The optimal dose for treating SLE is still being determined through these studies.
Potential Side Effects
As Cenerimod is still in clinical trials, the full range of potential side effects is not yet known. However, some areas of special interest being monitored in the trials include:
- Effects on heart rate and rhythm
- Changes in blood pressure (both high and low)
- Cardiovascular effects
- Liver-related issues
- Lung-related effects
- Eye disorders
- Increased risk of infections
- Potential for skin and non-skin cancers
It's important to note that these are potential risks being monitored, and not all patients may experience these side effects. The ongoing clinical trials will help determine the safety profile of Cenerimod.
Ongoing Research and Future Prospects
In addition to the main clinical trials for SLE, researchers are also investigating other aspects of Cenerimod:
- A study is looking at how Cenerimod affects the electrical activity of the heart (QT interval).
- Another study is examining how Cenerimod interacts with oral contraceptives.
- Researchers are also studying how Cenerimod is processed by the body in people with kidney or liver problems.
These additional studies will help researchers better understand how Cenerimod works in different situations and patient populations, potentially expanding its use in the future.